| Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis W Hanel, N Marchenko, S Xu, S Xiaofeng Yu, W Weng, U Moll Cell Death & Differentiation 20 (7), 898-909, 2013 | 271 | 2013 |
| Distinct functional motifs within the IL-17 receptor regulate signal transduction and target gene expression A Maitra, F Shen, W Hanel, K Mossman, J Tocker, D Swart, SL Gaffen Proceedings of the National Academy of Sciences 104 (18), 7506-7511, 2007 | 220 | 2007 |
| Links between mutant p53 and genomic instability W Hanel, UM Moll Journal of cellular biochemistry 113 (2), 433-439, 2012 | 217 | 2012 |
| Stress-mediated nuclear stabilization of p53 is regulated by ubiquitination and importin-α3 binding ND Marchenko, W Hanel, D Li, K Becker, N Reich, UM Moll Cell Death & Differentiation 17 (2), 255-267, 2010 | 128 | 2010 |
| CARMA1 coiled-coil domain is involved in the oligomerization and subcellular localization of CARMA1 and is required for T cell receptor-induced NF-κB activation MJ Tanner, W Hanel, SL Gaffen, X Lin Journal of Biological Chemistry 282 (23), 17141-17147, 2007 | 82 | 2007 |
| SEF/IL-17R (SEFIR) is not enough: an extended SEFIR domain is required for il-17RA-mediated signal transduction RM Onishi, SJ Park, W Hanel, AW Ho, A Maitra, SL Gaffen Journal of biological chemistry 285 (43), 32751-32759, 2010 | 80 | 2010 |
| Cutting edge: identification of a pre-ligand assembly domain (PLAD) and ligand binding site in the IL-17 receptor JM Kramer, W Hanel, F Shen, N Isik, JP Malone, A Maitra, W Sigurdson, ... The Journal of Immunology 179 (10), 6379-6383, 2007 | 70 | 2007 |
| A retrospective comparative outcome analysis following systemic therapy in M ycosis fungoides and S ezary syndrome W Hanel, R Briski, CW Ross, TF Anderson, MS Kaminski, AC Hristov, ... American Journal of Hematology 91 (12), E491-E495, 2016 | 54 | 2016 |
| Emerging therapies in mantle cell lymphoma W Hanel, N Epperla Journal of hematology & oncology 13, 1-18, 2020 | 52 | 2020 |
| Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies W Hanel, N Epperla Journal of Hematology & Oncology 14 (1), 104, 2021 | 17 | 2021 |
| Polo-like-kinase 1 (PLK-1) and c-myc inhibition with the dual kinase-bromodomain inhibitor volasertib in aggressive lymphomas C Murga-Zamalloa, A Polk, W Hanel, P Chowdhury, N Brown, AC Hristov, ... Oncotarget 8 (70), 114474, 2017 | 16 | 2017 |
| BCL-xL inhibition potentiates cancer therapies by redirecting the outcome of p53 activation from senescence to apoptosis V Bharti, R Watkins, A Kumar, RL Shattuck-Brandt, A Mossing, A Mittra, ... Cell reports 41 (12), 2022 | 13 | 2022 |
| Transducin b-like protein 1 controls multiple oncogenic networks in diffuse large B-cell lymphoma Y Youssef, V Karkhanis, WK Chan, F Jeney, A Canella, X Zhang, S Sloan, ... haematologica 106 (11), 2927, 2021 | 8 | 2021 |
| PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma SL Sloan, F Brown, M Long, C Weigel, S Koirala, JH Chung, B Pray, ... Blood 142 (10), 887-902, 2023 | 7 | 2023 |
| Outcomes of patients with limited‐stage plasmablastic lymphoma: a multi‐institutional retrospective study BT Hess, A Giri, Y Park, KK Patel, BK Link, GS Nowakowski, SM Maliske, ... American journal of hematology 98 (2), 300-308, 2023 | 7 | 2023 |
| A sumoylation program is essential for maintaining the mitotic fidelity in proliferating mantle cell lymphoma cells W Hanel, P Lata, Y Youssef, H Tran, L Tsyba, L Sehgal, BW Blaser, ... Experimental Hematology & Oncology 11 (1), 40, 2022 | 7 | 2022 |
| Management of classical Hodgkin lymphoma: a look at up to date evidence and current treatment approaches W Hanel, AF Herrera, N Epperla Experimental Hematology & Oncology 11 (1), 108, 2022 | 6 | 2022 |
| Impact of initial chemotherapy regimen on outcomes for patients with double‐expressor lymphoma: A multi‐center analysis CR D’angelo, W Hanel, Y Chen, M Yu, D Yang, L Guo, R Karmali, ... Hematological oncology 39 (4), 473-482, 2021 | 6 | 2021 |
| A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma W Hanel, P Shindiapina, DA Bond, Y Sawalha, N Epperla, T Voorhees, ... Cancers 15 (5), 1437, 2023 | 5 | 2023 |
| Extranodal natural killer/T-cell lymphomas: current approaches and future directions JC Reneau, P Shindiapina, Z Braunstein, Y Youssef, M Ruiz, S Farid, ... Journal of Clinical Medicine 11 (10), 2699, 2022 | 4 | 2022 |
